Picture

Northwestern Medicine
​Breakthroughs for Physicians

​​
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties

< BACK TO CLINICAL BREAKTHROUGHS IN GASTROENTEROLOGY

February 2022

GASTROENTEROLOGY

INTENSIVE CROHN’S TREATMENT IS SAFE

Featuring: Stephen Hanauer, MD
Intensive treatment for patients with Crohn’s disease showed no safety differences compared to the current standard of care, according to a trial published in the journal Gastroenterology.

The findings offer some additional flexibility for treating patients with Crohn’s disease, according to Stephen Hanauer, MD, the Clifford Joseph Barborka Professor of Medicine in the Division of Gastroenterology and Hepatology and a co-author of the study.

“This study shows some individuals respond to higher dosing, and importantly, there were no safety issues,” Hanauer said.

Crohn’s disease (CD) is a chronic, progressive inflammatory bowel disease, causing abdominal pain, weight loss and fatigue. Treatment for CD has typically focused on alleviating symptoms to achieve clinical remission using drugs such as adalimumab, a monoclonal antibody that reduces inflammatory cytokines.

Treatment efficacy will wane over time for about half of patients, requiring increased dosing to recapture treatment response, according to Hanauer. In the current study, investigators examined the impact of higher initial and maintenance dosing, hypothesizing that it may obviate the need for reactive dosing.

​The study measured outcomes by measuring symptomatic remission and using endoscopy, which can give a more precise picture of patient status, according to the study authors.

In this phase 3, randomized, double-blind trial, about 300 patients were randomized to an intensive treatment group while about 200 were randomized to a standard drug regimen. The intensive treatment group received weekly doses of 160 milligrams of adalimumab — a monoclonal antibody that reduces inflammatory cytokines — while the standard group received 80 milligrams per week.

Similar proportions of patients in both groups achieved clinical remission at week four (44 percent) and endoscopic response at week 12 (43 percent in intensive group, 39 percent in standard treatment group). Outcomes at one year were also not different between the groups.

There was no between-group difference in rates of adverse events, and maintenance-dose adjustment via serum adalimumab levels was not more efficacious than clinically adjusted dosing. According to Hanauer, these findings reinforce the efficacy of the standard regiment while opening the door to higher doses.

“While standard dosing is effective, individual patients may still require dose-escalations to achieve ‘optimal efficacy’ from adalimumab and this study does not rule out need for reactive drug level monitoring,” Hanauer said.

This trial was funded by Abbvie.

Stephen B Hanauer has been a consultant and/or speaker for AbbVie, Actavis, Allergan, Amgen, Arena Pharmaceuticals, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Ferring, Genentech, Gilead, GlaxoSmithKline, Gossamer, Janssen, Lilly, Merck, Nestlé, Novartis, Pfizer, Prometheus Biosciences, Protagonist, Salix, Samsung Bioepis, Sanofi, Seres Therapeutics, Shire, Takeda, and Therakos. He has received research grants from AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus Biosciences, Receptos (Celgene), and Sanofi.

​
This article was originally published in the Feinberg School of Medicine News Center on March 1, 2022. ​
Headshot of Stephen Hanauer, MD
Stephen Hanauer, MD, the Clifford Joseph Barborka Professor, was a co-author of the study published in the journal Gastroenterology.

​

Refer a Patient

Northwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients. ​
Call 844.344.6663
Find an NM Gastroenterologist

You May Also Like

 Clinician holding clipboard and speaking to patient in exam room

June 2021

GASTROENTEROLOGY
Black Patients with Cirrhosis Have Higher Mortality Rates
Video still of Dr. Daniel Ganger

March 2020

GASTROENTEROLOGY
Cirrhosis: Is Liver Transplantation Always Needed?
Headshots of Dr. Lisa VanWagner and Dr. Mary Rinella

May 2020

GASTROENTEROLOGY
Managing Nonalcoholic Fatty Liver Disease

Northwestern Medicine Breakthroughs for Physicians

About Us     Terms of Use     Privacy Policy     How to Vote for U.S. News & World Report Best Hospitals
© 2025 Northwestern Medicine® and Northwestern Memorial HealthCare. 
Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University
Connect with us
[email protected]
International physicians, contact [email protected]
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties